EyeGate Pharmaceuticals to Present at BIO CEO & Investor Conference in New York City
29 janv. 2019 06h55 HE
|
EyeGate Pharmaceuticals, Inc.
WALTHAM, Mass., Jan. 29, 2019 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or “the Company”) today announced that the Company will attend and present at the 21st BIO...
EyeGate Pharmaceuticals Announces Meeting Date with FDA
16 janv. 2019 06h55 HE
|
EyeGate Pharmaceuticals, Inc.
WALTHAM, Mass., Jan. 16, 2019 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or “the Company”) today confirmed that it is scheduled to meet with the U.S. Food and Drug...
EyeGate Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Business Update
13 nov. 2018 16h05 HE
|
EyeGate Pharmaceuticals, Inc.
WALTHAM, Mass., Nov. 13, 2018 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or “the Company”) today announced financial results for the three-month period ended...
EyeGate Pharma Announces Positive Results in Second PRK Study
13 nov. 2018 06h55 HE
|
EyeGate Pharmaceuticals, Inc.
Data confirms results from earlier study WALTHAM, Mass., Nov. 13, 2018 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) today announced top-line data from its study evaluating the...
EyeGate Pharma Announces Positive Results in Punctate Epitheliopathy Study
13 nov. 2018 06h55 HE
|
EyeGate Pharmaceuticals, Inc.
WALTHAM, Mass., Nov. 13, 2018 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) today announced top-line data from its study evaluating the potential of EyeGate’s Ocular Bandage Gel...
EyeGate Pharmaceuticals Signs Technology Transfer and License Agreement with SentrX Animal Care
02 oct. 2018 06h55 HE
|
EyeGate Pharmaceuticals, Inc.
WALTHAM, Mass., Oct. 02, 2018 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) a clinical-stage, specialty pharmaceutical company with two proprietary platform technologies for...
EyeGate Pharmaceuticals Granted Additional 180 Days to Comply With Nasdaq Listing Rules
25 sept. 2018 06h55 HE
|
EyeGate Pharmaceuticals, Inc.
WALTHAM, Mass., Sept. 25, 2018 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) a clinical-stage, specialty pharmaceutical company with two proprietary platform technologies for...
EyeGate Pharmaceuticals Completes Enrollment in Both PRK and PE Pilot Studies
24 sept. 2018 06h55 HE
|
EyeGate Pharmaceuticals, Inc.
WALTHAM, Mass., Sept. 24, 2018 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) a clinical-stage, specialty pharmaceutical company with two proprietary platform technologies for...
EyeGate Announces Randomization of First Patients in Study for Punctate Epitheliopathies
04 sept. 2018 08h31 HE
|
EyeGate Pharmaceuticals, Inc.
WALTHAM, Mass., Sept. 04, 2018 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) a clinical-stage, specialty pharmaceutical company with two proprietary platform technologies for...
EyeGate Announces Top-Line Results for Phase 3 Trial of EGP-437 in Anterior Uveitis
04 sept. 2018 08h30 HE
|
EyeGate Pharmaceuticals, Inc.
WALTHAM, Mass., Sept. 04, 2018 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) a clinical-stage, specialty pharmaceutical company with two proprietary platform technologies for...